2seventy bio, Inc. (TSVT)
NASDAQ: TSVT · Real-Time Price · USD
3.080
-0.030 (-0.96%)
Nov 21, 2024, 11:34 AM EST - Market open
Company Description
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States.
The company’s products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.
It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
2seventy bio, Inc.
| Country | United States |
| Founded | 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 274 |
| CEO | William Baird |
Contact Details
Address: 60 Binney Street Cambridge, Massachusetts 02142 United States | |
| Phone | 617 675 7270 |
| Website | 2seventybio.com |
Stock Details
| Ticker Symbol | TSVT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001860782 |
| CUSIP Number | 901384107 |
| ISIN Number | US9013841070 |
| Employer ID | 86-3658454 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| William D. Baird III, M.B.A. | Chief Executive Officer, President and Director |
| Victoria Eatwell | Chief Financial Officer |
| Jessica Snow | Senior Vice President of Quality and Head of Operations |
| Dr. Anna Truppel-Hartmann M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 18, 2024 | 144 | Filing |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 6, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 31, 2024 | 8-K | Current Report |
| Sep 25, 2024 | 8-K | Current Report |
| Aug 14, 2024 | 144 | Filing |
| Aug 8, 2024 | 10-Q | Quarterly Report |
| Aug 7, 2024 | 8-K | Current Report |
| Jul 26, 2024 | 8-K | Current Report |